TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Jinhai International Group Holdings Limited ( (HK:2225) ).
Jinhai Medical Technology Limited reported a significant decline in its financial performance for the first half of 2025, with revenue dropping from S$25,937,000 in 2024 to S$14,529,000 in 2025. The company faced a loss before tax of S$10,722,000, compared to a loss of S$5,941,000 in the same period last year, indicating challenges in maintaining profitability. This downturn in financial results could impact the company’s market positioning and stakeholder confidence.
The most recent analyst rating on (HK:2225) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on Jinhai International Group Holdings Limited stock, see the HK:2225 Stock Forecast page.
More about Jinhai International Group Holdings Limited
Jinhai Medical Technology Limited, listed on the Main Board of the Stock Exchange since October 2017, operates in the medical technology industry. The company focuses on providing medical technology products and services.
Average Trading Volume: 9,801,677
Technical Sentiment Signal: Sell
Current Market Cap: HK$2.65B
For a thorough assessment of 2225 stock, go to TipRanks’ Stock Analysis page.